Aimmune Therapeutics Names New Chief Operating Officer

Aimmune Therapeutics, Inc. (NASDAQ:AIMT) has named Jeffrey H. Knapp the company’s new Chief Operating Officer.

According to the press release:
Mr. Knapp brings a nearly 30-year track record of achievement in both large pharmaceutical and small biotechnology companies, including deep commercial experience and first-product launches. Mr. Knapp will join Aimmune on or about February 1, 2016.
“Jeff is the ideal executive to lead Aimmune’s operations into our next phase of development, as we execute on our Phase 3 PALISADE trial and prepare to potentially bring an effective treatment to protect peanut-allergic children, adolescents and adults,” said Aimmune CEO Stephen Dilly, M.B.B.S., Ph.D. “I look forward to partnering with Jeff as we scale up our manufacturing operations, prepare our go-to-market strategies, and begin to build a world-class commercial organization.”
Over his career, Mr. Knapp has led strategy and execution for multiple product launches across several therapeutic areas. Prior to Aimmune, Mr. Knapp was Chief Operating Officer at Adamas Pharmaceuticals, which he joined as Chief Commercial Officer in early 2014. He was previously Chief Commercial Officer at Affymax Inc., where, over seven years in the role, he built out the company’s U.S. commercial organization and led the launch of its first product. Mr. Knapp also led sales and marketing at Abgenix, Pharmion, and EMD Pharmaceuticals. He spent the first half of his career at Eli Lilly and Schering-Plough in various sales, marketing and business development roles. Mr. Knapp earned his bachelor’s degree in biology from Wittenberg University.

Click here to read the full press release.